Can Breast Milk Detect Cancer? What New Research from Clarkson University Says
17 janv. 2022 11h34 HE | Clarkson University
Potsdam, NY, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Samples from breast milk may one day be used routinely to identify cancer, or even to detect cancer risk. That’s the goal of the work of researchers...
Global Cancer Clinical Decision Tools Markets Analysis & Forecasts, 2015-2020, 2020-2025F, 2030F
10 janv. 2022 04h28 HE | Research and Markets
Dublin, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The "Cancer Clinical Decision Tools Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to's...
Kamran Tahamtanzadeh Joins Inanovate, Inc. as New Chief Executive Officer
04 janv. 2022 11h45 HE | Inanovate
SIOUX FALLS, S.D., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Inanovate Inc ("Inanovate") has announced the appointment of Kamran Tahamtanzadeh as Chief Executive Officer. Inanovate is a leading molecular...
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
10 déc. 2021 08h10 HE | Arvinas Inc.
– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium – – ARV-471 is...
G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
29 nov. 2021 07h00 HE | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2,...
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
19 nov. 2021 09h55 HE | Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose...
Global Breast Cancer Therapeutics Market to Exhibit 13.1% CAGR and Hit USD 55.27 Billion till 2027 | Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Fortune Business Insights™
17 nov. 2021 05h41 HE | Fortune Business Insights
Pune, India, Nov. 17, 2021 (GLOBE NEWSWIRE) -- The global breast cancer therapeutics market is set to gain impetus from the ongoing research and developments to come up with state-of-the-art drugs....
Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II
15 nov. 2021 10h00 HE | Sermonix Pharmaceuticals LLC
Funds will be used to further advance lasofoxifene through late-stage clinical development as a next-generation oral SERM to treat women with increasingly prevalent ESR1 breast cancer mutationsInitial...
Global Breast Cancer Drugs Market (2021 to 2030) - Players Include Novartis, AstraZeneca and Celgene Among Others
11 nov. 2021 06h58 HE | Research and Markets
Dublin, Nov. 11, 2021 (GLOBE NEWSWIRE) -- The "Breast Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to's offering. This...
July 30, 2021 - ROSEN LOGO.jpg
SBTX SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Silverback Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SBTX
10 nov. 2021 14h22 HE | The Rosen Law Firm PA
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...